Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The authors argue that chlorine dioxide (CD) is a safe and effective decontaminating agent that can be used for challenging applications.The effectiveness of CD gas for sterilizing complex isolator systems is studied.

Isolator Decontamination Using Chlorine Dioxide Gas

The authors study the effects of sweet potato and cocoyam starches on the compressional and mechanical characteristics of a paracetamol tablet formulation using cornstarch BP.

Compression and Mechanical Properties of Tablet Formulations: Containing Corn, Sweet Potato, and Cocoyam Starches as Binders

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Innovators and generics makers are staking out positions on follow-on proteins and other manufacturing issues.

Generic Drug Battles Heat Up

Inhalation Products Expert Groups: Helping to Fill the Gaps

Bruno C. Hancock is a scientist in the solids development group at Pfizer.

X-ray microtomography has great potential for improving the understanding of the structural features of solid dosage forms and the changes in those features during manufacturing, handling, and storage. This article describes the basic principles of the technique and provides examples of its potential applications.

X-ray Microtomography of Solid Dosage Forms

"Stable Liquid" Technology Permits Heptavalent Vaccine Against Botulism

UK MHRA Okays Chiron Flu Vaccine Plant; FDA Approval Still to Come

Big Pharma Companies Team Up to Develop Once-Daily, Triple-Combination HIV Drug

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

This article outlines a comprehensive approach for organizing a firm's aseptic operations, including planning for routine and nonroutine interventions, establishing effective process simulations, and determining which vials to incubate.

Managing Aseptic Interventions

New fixed-dose combination drugs aim to enhance safety and efficacy, while regulators clear a path for more drug–device combination products.